Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 68 entries
Sorted by: Best Match Show Resources per page
Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment.

Pediatric gastroenterology, hepatology & nutrition

Boga S, Jain D, Schilsky ML.
PMID: 26473142
Pediatr Gastroenterol Hepatol Nutr. 2015 Sep;18(3):202-8. doi: 10.5223/pghn.2015.18.3.202. Epub 2015 Sep 25.

Progressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal recessive disorder of cholestasis of hepatocellular origin, typically seen in infancy or childhood caused by a defect in the ABCB4 located on chromosome 7. Here we report on an...

Cite
Boga S, Jain D, Schilsky ML. Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment. Pediatr Gastroenterol Hepatol Nutr. 2015;18(3):202-8doi: 10.5223/pghn.2015.18.3.202.
Boga, S., Jain, D., & Schilsky, M. L. (2015). Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment. Pediatric gastroenterology, hepatology & nutrition, 18(3), 202-8. https://doi.org/10.5223/pghn.2015.18.3.202
Boga, Salih, et al. "Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment." Pediatric gastroenterology, hepatology & nutrition vol. 18,3 (2015): 202-8. doi: https://doi.org/10.5223/pghn.2015.18.3.202
Boga S, Jain D, Schilsky ML. Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment. Pediatr Gastroenterol Hepatol Nutr. 2015 Sep;18(3):202-8. doi: 10.5223/pghn.2015.18.3.202. Epub 2015 Sep 25. PMID: 26473142; PMCID: PMC4600706.
Copy Download .nbib Format: NLM
Current Management Strategies for Acute Esophageal Variceal Hemorrhage.

Current hepatology reports

Fortune B, Garcia-Tsao G.
PMID: 24955303
Curr Hepatol Rep. 2014 Mar 01;13(1):35-42. doi: 10.1007/s11901-014-0221-y.

Acute esophageal variceal hemorrhage is one of the clinical events that define decompensated cirrhosis and is associated with high rates of morbidity and mortality. Although recent treatment strategies have led to improved outcomes, variceal hemorrhage still carries a 6-week...

Cite
Fortune B, Garcia-Tsao G. Current Management Strategies for Acute Esophageal Variceal Hemorrhage. Curr Hepatol Rep. 2014;13(1):35-42doi: 10.1007/s11901-014-0221-y.
Fortune, B., & Garcia-Tsao, G. (2014). Current Management Strategies for Acute Esophageal Variceal Hemorrhage. Current hepatology reports, 13(1), 35-42. https://doi.org/10.1007/s11901-014-0221-y
Fortune, Brett, and Garcia-Tsao, Guadalupe. "Current Management Strategies for Acute Esophageal Variceal Hemorrhage." Current hepatology reports vol. 13,1 (2014): 35-42. doi: https://doi.org/10.1007/s11901-014-0221-y
Fortune B, Garcia-Tsao G. Current Management Strategies for Acute Esophageal Variceal Hemorrhage. Curr Hepatol Rep. 2014 Mar 01;13(1):35-42. doi: 10.1007/s11901-014-0221-y. PMID: 24955303; PMCID: PMC4061703.
Copy Download .nbib Format: NLM
Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C.

ACG case reports journal

Sarkar S, Mitchell KA, Lim JK, Oikonomou I, Jakab S.
PMID: 26504877
ACG Case Rep J. 2015 Oct 09;3(1):42-4. doi: 10.14309/crj.2015.96. eCollection 2015 Oct.

Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir. No prior...

Cite
Sarkar S, Mitchell KA, Lim JK, et al. Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. ACG Case Rep J. 2015;3(1):42-4doi: 10.14309/crj.2015.96.
Sarkar, S., Mitchell, K. A., Lim, J. K., Oikonomou, I., & Jakab, S. (2015). Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. ACG case reports journal, 3(1), 42-4. https://doi.org/10.14309/crj.2015.96
Sarkar, Souvik, et al. "Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C." ACG case reports journal vol. 3,1 (2015): 42-4. doi: https://doi.org/10.14309/crj.2015.96
Sarkar S, Mitchell KA, Lim JK, Oikonomou I, Jakab S. Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. ACG Case Rep J. 2015 Oct 09;3(1):42-4. doi: 10.14309/crj.2015.96. eCollection 2015 Oct. PMID: 26504877; PMCID: PMC4612757.
Copy Download .nbib Format: NLM
Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging.

PloS one

Gross M, Spektor M, Jaffe A, Kucukkaya AS, Iseke S, Haider SP, Strazzabosco M, Chapiro J, Onofrey JA.
PMID: 34852007
PLoS One. 2021 Dec 01;16(12):e0260630. doi: 10.1371/journal.pone.0260630. eCollection 2021.

PURPOSE: Accurate liver segmentation is key for volumetry assessment to guide treatment decisions. Moreover, it is an important pre-processing step for cancer detection algorithms. Liver segmentation can be especially challenging in patients with cancer-related tissue changes and shape deformation....

Cite
Gross M, Spektor M, Jaffe A, et al. Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging. PLoS One. 2021;16(12):e0260630doi: 10.1371/journal.pone.0260630.
Gross, M., Spektor, M., Jaffe, A., Kucukkaya, A. S., Iseke, S., Haider, S. P., Strazzabosco, M., Chapiro, J., & Onofrey, J. A. (2021). Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging. PloS one, 16(12), e0260630. https://doi.org/10.1371/journal.pone.0260630
Gross, Moritz, et al. "Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging." PloS one vol. 16,12 (2021): e0260630. doi: https://doi.org/10.1371/journal.pone.0260630
Gross M, Spektor M, Jaffe A, Kucukkaya AS, Iseke S, Haider SP, Strazzabosco M, Chapiro J, Onofrey JA. Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging. PLoS One. 2021 Dec 01;16(12):e0260630. doi: 10.1371/journal.pone.0260630. eCollection 2021. PMID: 34852007; PMCID: PMC8635384.
Copy Download .nbib Format: NLM
Recessive Mutations in .

Hepatology communications

Ünlüsoy Aksu A, Das SK, Nelson-Williams C, Jain D, Özbay Hoşnut F, Evirgen Şahin G, Lifton RP, Vilarinho S.
PMID: 30976738
Hepatol Commun. 2019 Feb 13;3(4):471-477. doi: 10.1002/hep4.1320. eCollection 2019 Apr.

Undiagnosed liver disease remains an unmet medical need in pediatric hepatology, including children with high gamma-glutamyltransferase (GGT) cholestasis. Here, we report whole-exome sequencing of germline DNA from 2 unrelated children, both offspring of consanguineous union, with neonatal cholestasis and...

Cite
Ünlüsoy Aksu A, Das SK, Nelson-Williams C, et al. Recessive Mutations in . Hepatol Commun. 2019;3(4):471-477doi: 10.1002/hep4.1320.
Ünlüsoy Aksu, A., Das, S. K., Nelson-Williams, C., Jain, D., Özbay Hoşnut, F., Evirgen Şahin, G., Lifton, R. P., & Vilarinho, S. (2019). Recessive Mutations in . Hepatology communications, 3(4), 471-477. https://doi.org/10.1002/hep4.1320
Ünlüsoy Aksu, Aysel, et al. "Recessive Mutations in ." Hepatology communications vol. 3,4 (2019): 471-477. doi: https://doi.org/10.1002/hep4.1320
Ünlüsoy Aksu A, Das SK, Nelson-Williams C, Jain D, Özbay Hoşnut F, Evirgen Şahin G, Lifton RP, Vilarinho S. Recessive Mutations in . Hepatol Commun. 2019 Feb 13;3(4):471-477. doi: 10.1002/hep4.1320. eCollection 2019 Apr. PMID: 30976738; PMCID: PMC6442693.
Copy Download .nbib Format: NLM
α-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study.

British journal of cancer

Lu SX, Huang YH, Liu LL, Zhang CZ, Yang X, Yang YZ, Shao CK, Li JM, Xie D, Zhang X, Jain D, Yun JP.
PMID: 33824478
Br J Cancer. 2021 Jun;124(12):1988-1996. doi: 10.1038/s41416-021-01363-4. Epub 2021 Apr 06.

BACKGROUND: Pathologic diagnosis of hepatocellular carcinoma (HCC) can be challenging in differentiating from benign and non-hepatocytic malignancy lesions. The aim of this study was to investigate the potential utility of α-fetoprotein (AFP) mRNA RNAscope, a sensitive and specific method,...

Cite
Lu SX, Huang YH, Liu LL, et al. α-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study. Br J Cancer. 2021;124(12):1988-1996doi: 10.1038/s41416-021-01363-4.
Lu, S. X., Huang, Y. H., Liu, L. L., Zhang, C. Z., Yang, X., Yang, Y. Z., Shao, C. K., Li, J. M., Xie, D., Zhang, X., Jain, D., & Yun, J. P. (2021). α-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study. British journal of cancer, 124(12), 1988-1996. https://doi.org/10.1038/s41416-021-01363-4
Lu, Shi-Xun, et al. "α-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study." British journal of cancer vol. 124,12 (2021): 1988-1996. doi: https://doi.org/10.1038/s41416-021-01363-4
Lu SX, Huang YH, Liu LL, Zhang CZ, Yang X, Yang YZ, Shao CK, Li JM, Xie D, Zhang X, Jain D, Yun JP. α-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study. Br J Cancer. 2021 Jun;124(12):1988-1996. doi: 10.1038/s41416-021-01363-4. Epub 2021 Apr 06. PMID: 33824478; PMCID: PMC8184895.
Copy Download .nbib Format: NLM
Fibrocystic liver disease: novel concepts and translational perspectives.

Translational gastroenterology and hepatology

Lasagni A, Cadamuro M, Morana G, Fabris L, Strazzabosco M.
PMID: 33824930
Transl Gastroenterol Hepatol. 2021 Apr 05;6:26. doi: 10.21037/tgh-2020-04. eCollection 2021.

Fibrocystic liver diseases (FLDs) comprise a heterogeneous group of rare diseases of the biliary tree, having in common an abnormal development of the embryonic ductal plate caused by genetically-determined dysfunctions of proteins expressed in the primary cilia of cholangiocytes...

Cite
Lasagni A, Cadamuro M, Morana G, et al. Fibrocystic liver disease: novel concepts and translational perspectives. Transl Gastroenterol Hepatol. 2021;6:26doi: 10.21037/tgh-2020-04.
Lasagni, A., Cadamuro, M., Morana, G., Fabris, L., & Strazzabosco, M. (2021). Fibrocystic liver disease: novel concepts and translational perspectives. Translational gastroenterology and hepatology, 626. https://doi.org/10.21037/tgh-2020-04
Lasagni, Alberto, et al. "Fibrocystic liver disease: novel concepts and translational perspectives." Translational gastroenterology and hepatology vol. 6 (2021): 26. doi: https://doi.org/10.21037/tgh-2020-04
Lasagni A, Cadamuro M, Morana G, Fabris L, Strazzabosco M. Fibrocystic liver disease: novel concepts and translational perspectives. Transl Gastroenterol Hepatol. 2021 Apr 05;6:26. doi: 10.21037/tgh-2020-04. eCollection 2021. PMID: 33824930; PMCID: PMC7838530.
Copy Download .nbib Format: NLM
Oxidative stress and genotoxicity in 1,4-dioxane liver toxicity as evidenced in a mouse model of glutathione deficiency.

The Science of the total environment

Chen Y, Wang Y, Charkoftaki G, Orlicky DJ, Davidson E, Wan F, Ginsberg G, Thompson DC, Vasiliou V.
PMID: 34600989
Sci Total Environ. 2022 Feb 01;806:150703. doi: 10.1016/j.scitotenv.2021.150703. Epub 2021 Sep 30.

1,4-Dioxane (DX) is a synthetic chemical used as a stabilizer for industrial solvents. Recent occurrence data show widespread and significant contamination of drinking water with DX in the US. DX is classified by the International Agency for Research on...

Cite
Chen Y, Wang Y, Charkoftaki G, et al. Oxidative stress and genotoxicity in 1,4-dioxane liver toxicity as evidenced in a mouse model of glutathione deficiency. Sci Total Environ. 2021;806:150703doi: 10.1016/j.scitotenv.2021.150703.
Chen, Y., Wang, Y., Charkoftaki, G., Orlicky, D. J., Davidson, E., Wan, F., Ginsberg, G., Thompson, D. C., & Vasiliou, V. (2022). Oxidative stress and genotoxicity in 1,4-dioxane liver toxicity as evidenced in a mouse model of glutathione deficiency. The Science of the total environment, 806150703. https://doi.org/10.1016/j.scitotenv.2021.150703
Chen, Ying, et al. "Oxidative stress and genotoxicity in 1,4-dioxane liver toxicity as evidenced in a mouse model of glutathione deficiency." The Science of the total environment vol. 806 (2022): 150703. doi: https://doi.org/10.1016/j.scitotenv.2021.150703
Chen Y, Wang Y, Charkoftaki G, Orlicky DJ, Davidson E, Wan F, Ginsberg G, Thompson DC, Vasiliou V. Oxidative stress and genotoxicity in 1,4-dioxane liver toxicity as evidenced in a mouse model of glutathione deficiency. Sci Total Environ. 2022 Feb 01;806:150703. doi: 10.1016/j.scitotenv.2021.150703. Epub 2021 Sep 30. PMID: 34600989; PMCID: PMC8633123.
Copy Download .nbib Format: NLM
The role of bile acids in cholestatic liver injury.

Annals of translational medicine

Cai SY, Boyer JL.
PMID: 33987435
Ann Transl Med. 2021 Apr;9(8):737. doi: 10.21037/atm-20-5110.

Clinical disorders that impair bile flow result in retention of bile acids and cholestatic liver injury, characterized by parenchymal cell death, bile duct proliferation, liver inflammation and fibrosis. However, the pathogenic role of bile acids in the development of...

Cite
Cai SY, Boyer JL. The role of bile acids in cholestatic liver injury. Ann Transl Med. 2021;9(8):737doi: 10.21037/atm-20-5110.
Cai, S. Y., & Boyer, J. L. (2021). The role of bile acids in cholestatic liver injury. Annals of translational medicine, 9(8), 737. https://doi.org/10.21037/atm-20-5110
Cai, Shi-Ying, and Boyer, James L. "The role of bile acids in cholestatic liver injury." Annals of translational medicine vol. 9,8 (2021): 737. doi: https://doi.org/10.21037/atm-20-5110
Cai SY, Boyer JL. The role of bile acids in cholestatic liver injury. Ann Transl Med. 2021 Apr;9(8):737. doi: 10.21037/atm-20-5110. PMID: 33987435; PMCID: PMC8106037.
Copy Download .nbib Format: NLM
Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection.

Patient preference and adherence

Clark BT, Garcia-Tsao G, Fraenkel L.
PMID: 22536063
Patient Prefer Adherence. 2012;6:285-95. doi: 10.2147/PPA.S30111. Epub 2012 Apr 04.

OBJECTIVES: Guidelines for hepatitis C (HCV) strongly recommend antiviral treatment for patients with more severe liver disease given their increased risk of developing cirrhosis and other liver-related complications. Despite the proven benefits of therapy, 70%-88% of patients chronically infected...

Cite
Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence. 2012;6:285-95doi: 10.2147/PPA.S30111.
Clark, B. T., Garcia-Tsao, G., & Fraenkel, L. (2012). Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient preference and adherence, 6285-95. https://doi.org/10.2147/PPA.S30111
Clark, Brian T, et al. "Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection." Patient preference and adherence vol. 6 (2012): 285-95. doi: https://doi.org/10.2147/PPA.S30111
Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence. 2012;6:285-95. doi: 10.2147/PPA.S30111. Epub 2012 Apr 04. PMID: 22536063; PMCID: PMC3333810.
Copy Download .nbib Format: NLM
TNFSF15 Promotes Antimicrobial Pathways in Human Macrophages and These Are Modulated by TNFSF15 Disease-Risk Variants.

Cellular and molecular gastroenterology and hepatology

Sun R, Hedl M, Abraham C.
PMID: 32827707
Cell Mol Gastroenterol Hepatol. 2021;11(1):249-272. doi: 10.1016/j.jcmgh.2020.08.003. Epub 2020 Aug 19.

BACKGROUND & AIMS: TNFSF15 genetic variants leading to increased TNF superfamily member 15 (TNFSF15) expression confer risk for inflammatory bowel disease (IBD), and TNFSF15 is being explored as a therapeutic target in IBD patients. Although the focus for TNFSF15-mediated...

Cite
Sun R, Hedl M, Abraham C. TNFSF15 Promotes Antimicrobial Pathways in Human Macrophages and These Are Modulated by TNFSF15 Disease-Risk Variants. Cell Mol Gastroenterol Hepatol. 2020;11(1):249-272doi: 10.1016/j.jcmgh.2020.08.003.
Sun, R., Hedl, M., & Abraham, C. (2021). TNFSF15 Promotes Antimicrobial Pathways in Human Macrophages and These Are Modulated by TNFSF15 Disease-Risk Variants. Cellular and molecular gastroenterology and hepatology, 11(1), 249-272. https://doi.org/10.1016/j.jcmgh.2020.08.003
Sun, Rui, et al. "TNFSF15 Promotes Antimicrobial Pathways in Human Macrophages and These Are Modulated by TNFSF15 Disease-Risk Variants." Cellular and molecular gastroenterology and hepatology vol. 11,1 (2021): 249-272. doi: https://doi.org/10.1016/j.jcmgh.2020.08.003
Sun R, Hedl M, Abraham C. TNFSF15 Promotes Antimicrobial Pathways in Human Macrophages and These Are Modulated by TNFSF15 Disease-Risk Variants. Cell Mol Gastroenterol Hepatol. 2021;11(1):249-272. doi: 10.1016/j.jcmgh.2020.08.003. Epub 2020 Aug 19. PMID: 32827707; PMCID: PMC7689184.
Copy Download .nbib Format: NLM
Molecular Mechanism for Protection Against Liver Failure in Human Yellow Fever Infection.

Hepatology communications

Lemos FO, França A, Lima Filho ACM, Florentino RM, Santos ML, Missiaggia DG, Rodrigues GOL, Dias FF, Souza Passos IB, Teixeira MM, Andrade AMF, Lima CX, Vidigal PVT, Costa VV, Fonseca MC, Nathanson MH, Leite MF.
PMID: 32363317
Hepatol Commun. 2020 Mar 16;4(5):657-669. doi: 10.1002/hep4.1504. eCollection 2020 May.

Yellow fever (YF) is a viral hemorrhagic fever that typically involves the liver. Brazil recently experienced its largest recorded YF outbreak, and the disease was fatal in more than a third of affected individuals, mostly because of acute liver...

Cite
Lemos FO, França A, Lima Filho ACM, et al. Molecular Mechanism for Protection Against Liver Failure in Human Yellow Fever Infection. Hepatol Commun. 2020;4(5):657-669doi: 10.1002/hep4.1504.
Lemos, F. O., França, A., Lima Filho, A. C. M., Florentino, R. M., Santos, M. L., Missiaggia, D. G., Rodrigues, G. O. L., Dias, F. F., Souza Passos, I. B., Teixeira, M. M., Andrade, A. M. F., Lima, C. X., Vidigal, P. V. T., Costa, V. V., Fonseca, M. C., Nathanson, M. H., & Leite, M. F. (2020). Molecular Mechanism for Protection Against Liver Failure in Human Yellow Fever Infection. Hepatology communications, 4(5), 657-669. https://doi.org/10.1002/hep4.1504
Lemos, Fernanda de Oliveira, et al. "Molecular Mechanism for Protection Against Liver Failure in Human Yellow Fever Infection." Hepatology communications vol. 4,5 (2020): 657-669. doi: https://doi.org/10.1002/hep4.1504
Lemos FO, França A, Lima Filho ACM, Florentino RM, Santos ML, Missiaggia DG, Rodrigues GOL, Dias FF, Souza Passos IB, Teixeira MM, Andrade AMF, Lima CX, Vidigal PVT, Costa VV, Fonseca MC, Nathanson MH, Leite MF. Molecular Mechanism for Protection Against Liver Failure in Human Yellow Fever Infection. Hepatol Commun. 2020 Mar 16;4(5):657-669. doi: 10.1002/hep4.1504. eCollection 2020 May. PMID: 32363317; PMCID: PMC7193135.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 68 entries